TC BioPharm Ltd (TCBP) Stock Analysis

$0.500

-0.338 (-67.53%)At close

Loading chart…

High: 1.540
Open: 1.510
VWAP: 0.85
Vol: 5.90M
Mkt Cap: 4.10M
Low: 0.500
Amount: 4.99M
EV/EBITDA, TTM: 0.00

TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

www.tcbiopharm.com

Valuation Metrics

The current forward P/E ratio for TC BioPharm Ltd (TCBP) is 0.00, compared to its 5-year average forward P/E of -0.46.

Forward P/E

Fair

5Y Average P/E

-0.46

Current P/E

0.00

Overvalued

1.42

Undervalued

-2.33

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Fair

5Y Average P/S

1.67

Current P/S

0.00

Overvalued

4.86

Undervalued

-1.53

Events Timeline

2025-11-18 (ET)

09:33:16

CytoMed finalizes purchase of TC BioPharm's T cell technology

2025-06-11 (ET)

08:32:58

TC Biopharm reports first patient remission in Cohort B after TCB008 treatment

2025-03-21 (ET)

10:46:52

TC Biopharm announces transition to OTC Markets from Nasdaq

2025-03-18 (ET)

08:08:03

TC Biopharm launches cost reduction initiatives

2025-03-05 (ET)

08:32:02

TC Biopharm executes non-binding LoI to acquire pharmaceutical company

Show More Events

News

TCBP FAQ — answered by Alphio AI

TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows the Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product being used for the treatment of acute myeloid leukemia (AML). The Company has completed a Phase II clinical trial. Its CAR-T programs include in-house and partner programs at the pre-clinical-stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.